| Literature DB >> 25668201 |
Marion Mathieu1, Constance Hammond2, David G Karlin1.
Abstract
Genuine partnership between patient groups and medical experts is important but challenging. Our training program meets this challenge by organizing hands-on, lab-based training sessions for members of patient groups. These sessions allow "trainees" to better understand their disease and the biomedical research process, and strengthen links between patients and local researchers. Over the past decade, we and our partner institutes have received more than 900 French patients, with the participation of over 60 researchers and clinicians.Entities:
Mesh:
Year: 2015 PMID: 25668201 PMCID: PMC4323103 DOI: 10.1371/journal.pbio.1002067
Source DB: PubMed Journal: PLoS Biol ISSN: 1544-9173 Impact factor: 8.029
Aspects of the scientific method that patients often understand poorly.
| Aspects poorly understood | Comments | Notions explained during the training |
|---|---|---|
| The time scale of research | The time scale of research is always too long when compared to the life expectancy of a sick child or adult. | Patients experience by themselves the duration of experiments, the necessity of carrying out control experiments, and replicates. |
| The provisional nature of scientific knowledge | Members of patient groups can get unrealistic expectations about a hyped research avenue. | We give examples of promising or attractive research avenues that did not work out and emphasize the need to replicate published research. |
| The interconnection of research fields | Members of patient groups often do not realize that allocating funds to research on a given disease may benefit other diseases. | We give examples related to their disease. For instance, in a session on dystonia, we explained how deep brain stimulation, designed at first for essential tremor, is now used for dystonia and many other neurological diseases [ |
| The importance of animal models | Members of patient groups know little about animal models used in labs and often think that apes are the only relevant models for human diseases. | We present various animal models available for their pathology and how researchers choose models. We experiment either on a model organism of their disease or on the simplest genetically modified organism, bacteria. We present the difficulties, limits (practical, legal, and ethical), and costs of animal models. |
| The cost of research | Members of patient groups often have a poor idea of research costs, despite the fact that they often fund research. | We give examples of the cost of equipment and consumables they use (microscopes, enzymes...), and of building and running a lab. |
Examples of common questions that trainees and experts would like us to clarify during the training session.
| Frequent questions of trainees in relation with genetic diseases |
|---|
| - How can one identify a gene(s) associated with a disease? |
| - What is the relationship between mutations and symptoms? |
| - How do mutations cause a disease? |
| - Why does the diagnosis take so long? |
| - Why are results of research involving my biological samples not systematically communicated to me? |
| - Is there any research on my disease? |
| - Now that the gene has been discovered, why is there no treatment? |
| - What is the origin of my mutation (why and how did it happen?) |
| - How is the mutation transmitted between generations? |
|
|
| - Can I transmit my autoimmune disease to my children? |
| - I do not have a given disease predisposition gene marker, yet I have the corresponding disease—is that possible? How come? (For instance, I am not HLA-B27 but I am told I have spondylarthritis. Is it possible? Why?) |
| - What proportion do genes play in my disease? |
| - What are good biological markers of my disease? |
| - How can I predict outbreaks of my disease? |
| - How do biotherapies work? |
|
|
| Patients often do not understand: |
| - the biological causes of a disease (and thus what can be done to remediate it); |
| - that researchers cannot answer all their questions; |
| - how clinical trials work in practice; |
| - the time scale of research, which is not the same for patients and for researchers; |
| - that to be included in a long-term trial implies not only to not be included in other trials during that time but also during a certain period after the end of the trial (period of “noninclusion”); the necessity of placebos. |
Fig 1Layout of a typical training session for patient groups with a genetic disease.
See also Fig. 2 for how we tailor each training session to a particular disease.
Fig 2How we tailor practical workshops for a given disease based on the stage of research.
Fig 3Layout of a typical training session for patient groups with an autoimmune or autoinflammatory disease.